We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT (SAFEbt)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01312675
Recruitment Status : Terminated (Study stopped for operational futility. Due to very small numbers of subjects, insufficient data was available for results to provide meaningful conclusions.)
First Posted : March 11, 2011
Last Update Posted : February 9, 2018
Information provided by (Responsible Party):
B. Braun Medical Inc.

March 8, 2011
March 11, 2011
February 9, 2018
April 2011
March 2015   (Final data collection date for primary outcome measure)
Sequential Organ Failure Assessment (SOFA) Score [ Time Frame: Baseline through Day 8 ]
The primary outcome measure is the average of all changes in daily Sequential Organ Failure Assessment (SOFA) scores from baseline through Day 8.
Same as current
Complete list of historical versions of study NCT01312675 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT
Randomized, Multi-Centre, Controlled Clinical Study on Effect of the Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) Therapy on Disease Severity and Inflammation in Mechanically-Ventilated Subjects Due to Severe Sepsis
The purpose of this study is to determine if Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) therapy is effective in the treatment of severe sepsis.
Is extracorporeal treatment effective in the treatment of sepsis
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Severe Sepsis
Device: S.A.F.E.BT
Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
  • Experimental: Group A
    S.A.F.E.BT plus Standard of Care therapy
    Intervention: Device: S.A.F.E.BT
  • No Intervention: Group B
    Standard of Care therapy alone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2015
March 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Clinical diagnosis of Sepsis
  • Mechanical ventilation due to acute pulmonary dysfunction
  • One additional (second) acute sepsis-related organ dysfunction

Exclusion Criteria

  • Pregnant women and nursing mothers
  • Conditions or medications associated with an increased risk of bleeding/complications from anticoagulation
  • Previous episode of sepsis during this hospitalization
  • PaO2/FiO2 ratio < 300
  • Severe granulocytopenia (leukocytes <500 / μl)
  • Acute hepatic diseases or severe liver failure or cirrhosis
  • Chronic cardiovascular disease precluding extracorporeal treatment
  • Human immunodeficiency virus complicated by AIDS defining illness
  • Evidence of active bleeding - uncontrolled hemorrhage
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Plan to Share IPD: No
B. Braun Medical Inc.
B. Braun Medical Inc.
Not Provided
Study Director: Robert Wilkins, MBChB FRCA BBraun Inc
B. Braun Medical Inc.
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP